scispace - formally typeset
S

Stafford L. Lightman

Researcher at University of Bristol

Publications -  726
Citations -  39578

Stafford L. Lightman is an academic researcher from University of Bristol. The author has contributed to research in topics: Vasopressin & Corticosterone. The author has an hindex of 98, co-authored 714 publications receiving 36735 citations. Previous affiliations of Stafford L. Lightman include Bristol Royal Infirmary & University of Copenhagen.

Papers
More filters
Journal ArticleDOI

The HPA axis in major depression: classical theories and new developments

TL;DR: It is shown that hyperactivity of the hypothalamic-pituitary-adrenal axis is one of the most consistent biological findings in major depression psychiatry, but the mechanisms underlying this abnormality are still unclear.
Journal ArticleDOI

Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats.

TL;DR: Oxytocin exerts a central anxiolytic-like effect on both endocrine and behavioral systems and could play a role in moderating behavioral and physiological responses to stress.
Journal ArticleDOI

Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination.

TL;DR: Elderly carers of spouses with dementia have increased activation of the hypothalamic-pituitary-adrenal axis and a poor antibody response to influenza vaccine, and carers may be more vulnerable to infectious disease than the population of a similar age.
Journal ArticleDOI

Transcription Factor AP1 Potentiates Chromatin Accessibility and Glucocorticoid Receptor Binding

TL;DR: A model in which the basal occupancy of transcription factors acts to prime chromatin and direct inducible transcription factors to select regions in the genome is proposed, and the maintenance of baseline chromatin accessibility facilitates GR recruitment and is dependent on AP1 binding.
Journal ArticleDOI

Tryptophan metabolism in the central nervous system: medical implications

TL;DR: The molecular mechanisms involved in regulating the metabolism of tryptophan are discussed, the medical implications associated with dysregulation of both serotonergic and kynurenine pathways of tryPTophan metabolism are considered and the pathophysiology of conditions such as acquired immunodeficiency syndrome, Huntington's disease and Alzheimer's disease is considered.